Form 8-K

8-K — Opus Genetics, Inc.

Accession: 0001140361-26-025440

Filed: 2026-06-16

Period: 2026-06-16

CIK: 0001228627

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20076319_form8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20076319_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20076319_form8k.htm · Sequence: 1

false0001228627NASDAQ00012286272026-06-162026-06-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-34079

11-3516358

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

8 Davis Drive

Durham, NC

27713

(Address of principal executive offices)

(Zip Code)

(984) 884-6030

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IRD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On June 16, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release entitled “Opus

Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases.” A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by

reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company

undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated June 16, 2026.

104.1

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

OPUS GENETICS, INC.

Date: June 16, 2026

By:

/s/ Dr. George Magrath

Name:

Dr. George Magrath

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20076319_ex99-1.htm · Sequence: 2

Exhibit 99.1

Opus Genetics Highlights Five Gene Therapy Programs Targeting

Significant Unmet Need in Patients with Inherited Retinal Diseases

Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027

RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months

Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority

Review Vouchers

IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’

Pipeline

RESEARCH TRIANGLE PARK, N.C. – June 16, 2026 - Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage

biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), hosted a Research and Development (R&D) Science Forum where management and leading IRD experts

highlighted the Company’s expanding gene therapy pipeline for severe retinal diseases. The event highlighted three new programs entering clinical testing, recent LCA5 and BEST1 clinical data, the global IRD market opportunity, and clinical

development and execution strategies.

“As featured in our R&D Science Forum, our validated scientific approach and early clinical success provides strong momentum as we expand into our new

set of promising programs,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “We have first‑mover advantage across multiple indications, supported by broad intellectual property protection, rare‑disease regulatory pathways that

may offer flexibility and accelerated approval, and the potential for Orphan Drug exclusivity and Priority Review Vouchers. Our approach emphasizes streamlined timelines, capital‑efficient development, a premier collection of scientific advisors, and

an experienced leadership team capable of executing multiple clinical programs in parallel.”

A replay of the event and copy of the slide presentation may be accessed on Opus Genetics’ website under the Investors section: Events.

Gene Therapy Program Highlights

OPGx-RDH12

•

RDH12 mutations cause a severe form of Leber congenital amaurosis (LCA), which leads to early, rapid vision loss in infancy or childhood, often

resulting in legal blindness before the third decade of life.

•

Estimated global prevalence is 30,900 patients, including 2,500 patients in the U.S. and 17,500 patients in the Middle East / North Africa.*

•

OPGx-RDH12 is designed to restore a key component of the visual cycle.

•

In preclinical studies, OPGx-RDH12 delivered a functional RDH12 enzyme in vivo and restored structure and function in a small animal model.

•

This program is expected to initiate clinical testing in the U.S. in the fourth quarter of 2026. Funding is supported by the RDH12 Alliance.

OPGx-MERTK

•

MERTK mutations cause a severe form of autosomal recessive retinitis pigmentosa, which has an early-onset (childhood or adolescence) and

results in rapid vision loss.

•

Estimated global prevalence is 21,960 patients, including 2,600 patients in the U.S. and 14,300 patients in the Middle East / North Africa.*

•

OPGx-MERTK is designed to restore critical retinal pigment epithelium metabolic functions.

•

In preclinical studies, OPGx-MERTK provided evidence of retinal preservation of structure/ function and preserved outer nuclear layer thickness

in a small animal model of retinal degeneration.

•

This program is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027. Funding is supported by a

consortium led by Abu Dhabi’s Healthcare Research and Innovation Fund.

OPGx-RHO

•

RHO mutations cause autosomal-dominant retinitis pigmentosa, a highly variable, often slowly progressive rod-cone dystrophy characterized by

misfolded or dysfunctional rhodopsin that drives photoreceptor stress and progressive peripheral field loss followed by central vision decline.

•

Estimated global prevalence is 30,200 patients, including 8,800 patients in the U.S.*

•

OPGx-RHO is designed to “silence and replace” in autosomal dominant RHO.

•

In preclinical studies, OPGx-MERTK maintained rod morphology in the retinas in two large animal models.

•

This program is expected to initiate clinical testing globally in the second half of 2027.

OPGx-LCA5

•

LCA5 mutations cause a very early onset, severe disease typically presenting in infancy or early childhood.

•

Estimated global prevalence is 3,240 patients, including 170 patients in the U.S.*

•

OPGx-LCA5 is designed to restore the lack of functioning lebercilin, a key protein of the visual cycle, which severely impairs photoreceptor

function.

•

In the ongoing Phase 1/2 clinical trial, visual acuity was improved and maintained in the adult cohort over 24 months and improved in the

pediatric cohort over 6 months. In addition, the full-field stimulus test (FST) demonstrated durable vision improvement and microperimetry data provided evidence of increased sensitivity and movement of fixation toward the fovea.

•

Recruitment is ongoing in the run-in period for the pivotal Phase 3 trial. In parallel, the clinical and commercial batch of drug product is being

manufactured. Dosing with OPGx-LCA5 is expected to start in the fourth quarter of 2026.

OPGx-BEST1

•

BEST1 mutations disrupt cellular ion and fluid homeostasis resulting in electrophysiological abnormalities, RPE dysfunction, and retinal

degeneration, with a range of onset from childhood to adulthood and a slow rate of progression.

•

Estimated global prevalence is 21,800 patients, including 8,400 patients in the U.S. comprised of approximately 8,000 best vitelliform macular

dystrophy (BVMD) and approximately 400 autosomal recessive bestrophinopathy (ARB).*

•

OPGx-BEST1 is designed to target retinal pigment epithelium (RPE) cells and restore bestrophin function.

•

In the ongoing Phase 1/2 clinical trial, three BVMD and two ARB participants were enrolled in the first cohort, with dosing completed in May

2026.

•

Three-month topline data from Cohort 1 is expected in September 2026.

Commercial Market Opportunity

•

IRD patient prevalence across select global markets provides significant commercial market opportunity across Opus’ pipeline.

•

IRD prevalence may be higher than current estimates in some mutations. For example, patients may not undergo genetic testing when clinicians

diagnose BEST1 disease based on the presence of a characteristic vitelliform (“egg-yolk”) lesion beneath the macula.

* Triangle Insights Analysis of 5 Key Markets, 2026

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited

retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related

mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Forward-Looking Statements

This press release contains certain statements that are not statements of historical fact and are forward-looking statements within the meaning of

Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to

cash runway and future financing availability, potential product approvals, and Priority Review Voucher opportunities, the clinical development, clinical results, preclinical data and future plans for OPGx-LCA5, OPGx-BEST1, OPGx-MERTK, OPGx-RDH12,

OPGx-RHO and earlier stage programs, and expectations regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business,

prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk

Factors” included in our most recent Annual Report on Form 10-K for the year ended December 31, 2025 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing

of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,”

“continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking

statements contain these words. We undertake no obligation to publicly update any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:

Investors

Jenny Kobin

Remy Bernarda

IR Advisory Solutions

ir@opusgtx.com

Media

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Jun. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 16, 2026

Entity File Number

001-34079

Entity Registrant Name

Opus Genetics, Inc.

Entity Central Index Key

0001228627

Entity Incorporation, State or Country Code

Entity Tax Identification Number

11-3516358

Entity Address, Address Line One

8 Davis Drive

Entity Address, City or Town

Durham

Entity Address, State or Province

Entity Address, Postal Zip Code

27713

City Area Code

984

Local Phone Number

884-6030

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

IRD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration